CSL and Alentis Partner on Rare Kidney and Liver Disease Treatment
CSL and Alentis Therapeutics have entered into a global partnership to develop and commercialize the drug candidate lixudebart. The therapy is being investigated for rare kidney and liver diseases.
Biopharmaceutical companies CSL and Alentis Therapeutics announced a global collaboration to develop and commercialize lixudebart, a drug candidate targeting rare kidney and liver diseases. The therapy is intended to treat conditions such as acute kidney injury and certain liver diseases.
Under the agreement, Alentis will receive an upfront payment of $355 million from CSL. The Swiss biotechnology firm could also receive up to $1.2 billion in commercial milestone payments, along with a global profit share. CSL will lead the further development and marketing of the drug candidate.
Alentis Therapeutics focuses on developing treatments for rare diseases, while CSL is known for its work in plasma-derived and recombinant therapies. This partnership aims to accelerate the availability of lixudebart for patients who currently have limited therapeutic options.
The collaboration highlights the growing focus on rare disease treatments within the pharmaceutical sector. Both companies expect the partnership to advance the potential of lixudebart as a new treatment option worldwide.